Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

OBJECTIVE: To assess the long-term efficacy and safety of infliximab plus methotrexate in juvenile rheumatoid arthritis (JRA). METHODS: Patients eligible for the open-label extension (OLE, weeks 52–204) received infliximab 3–6 mg/kg every 8 weeks plus methotrexate. RESULTS: Of the 78/122 (64%) child...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruperto, Nicolino, Lovell, Daniel J, Cuttica, Ruben, Woo, Patricia, Meiorin, Silvia, Wouters, Carine, Silverman, Earl D, Balogh, Zsolt, Henrickson, Michael, Davidson, Joyce, Foeldvari, Ivan, Imundo, Lisa, Simonini, Gabriele, Oppermann, Joachim, Xu, Stephen, Shen, Yaung-Kaung, Visvanathan, Sudha, Fasanmade, Adedigbo, Mendelsohn, Alan, Martini, Alberto, Giannini, Edward H
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2009
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946101/
https://www.ncbi.nlm.nih.gov/pubmed/20237125
http://dx.doi.org/10.1136/ard.2009.100354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946101/
https://www.ncbi.nlm.nih.gov/pubmed/20237125
http://dx.doi.org/10.1136/ard.2009.100354

Ejemplares similares